Amicus Therapeutics (FOLD)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.07 (+0.72%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Amicus Therapeutics (FOLD)
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Key Insights

Critical company metrics and information
  • Share Price

    $9.86
  • Market Cap

    $2.95 Billion
  • Total Outstanding Shares

    298.81 Million Shares
  • Total Employees

    517
  • Dividend

    No dividend
  • IPO Date

    May 31, 2007
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.amicusrx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Exchange Gains/Losses$-11.04 Million
Net Cash Flow From Investing Activities, Continuing$-4.13 Million
Net Cash Flow$-29.45 Million
Net Cash Flow From Investing Activities$-4.13 Million
Net Cash Flow From Financing Activities$12.23 Million
Net Cash Flow From Operating Activities, Continuing$-26.52 Million
Net Cash Flow, Continuing$-18.41 Million
Net Cash Flow From Financing Activities, Continuing$12.23 Million
Net Cash Flow From Operating Activities$-26.52 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Basic Average Shares$305.64 Million
Costs And Expenses$562.02 Million
Gross Profit$444.24 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Operating Expenses$439.03 Million
Income Tax Expense/Benefit$36.34 Million
Benefits Costs and Expenses$562.02 Million
Income/Loss From Continuing Operations Before Tax$-68.35 Million
Operating Income/Loss$5.21 Million
Diluted Average Shares$305.64 Million
Income Tax Expense/Benefit, Deferred$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss$-104.69 Million
Net Income/Loss Attributable To Parent$-104.69 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Cost Of Revenue$49.43 Million
Net Income/Loss Available To Common Stockholders, Basic$-104.69 Million
Revenues$493.67 Million
Selling, General, and Administrative Expenses$306.95 Million
Income/Loss From Continuing Operations After Tax$-104.69 Million
Diluted Earnings Per Share$0.34
Other Operating Expenses$132.08 Million
Basic Earnings Per Share$0.34

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Non-current Liabilities$60.10 Million
Accounts Payable$13.48 Million
Other Non-current Assets$239.62 Million
Equity$178.82 Million
Intangible Assets$18.03 Million
Liabilities$607.73 Million
Current Assets$498.47 Million
Current Liabilities$158.14 Million
Other Current Assets$383.14 Million
Equity Attributable To Parent$178.82 Million
Long-term Debt$389.49 Million
Liabilities And Equity$786.56 Million
Assets$786.56 Million
Inventory$115.34 Million
Noncurrent Assets$288.08 Million
Other Current Liabilities$144.66 Million
Equity Attributable To Noncontrolling Interest$0.00
Noncurrent Liabilities$449.59 Million
Fixed Assets$30.44 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.